![]() If hypercalcemia does occur, appropriate treatment measures should be initiated. Hypercalcemia has been reported in some breast cancer patients with bone metastases after starting treatment with ZOLADEX. Patients receiving a GnRH agonist should be monitored for symptoms and signs suggestive of development of cardiovascular disease and be managed according to current clinical practice. Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with use of GnRH agonists like ZOLADEX in men. Monitor blood glucose levels and glycosylated hemoglobin (HbA1c) periodically and manage according to current clinical practice. Hyperglycemia and an increased risk of developing diabetes or worsening of glycemic control in patients with diabetes have been reported in men receiving GnRH agonists like ZOLADEX. Monitor patients at risk for complications of tumor flare. Some patients may experience a temporary increase in bone pain. Transient worsening of tumor symptoms, or the occurrence of additional signs and symptoms of breast cancer, may occasionally develop during the first few weeks of treatment. ![]() Effective nonhormonal contraception must be used by all premenopausal women during ZOLADEX therapy and for 12 weeks following discontinuation of therapy. ![]() Women should be advised against becoming pregnant while taking ZOLADEX. Pregnancy must be excluded for use in benign gynecological conditions. ZOLADEX should not be given to women with undiagnosed abnormal vaginal bleeding. There is an increased risk for pregnancy loss due to expected hormonal changes that occur with ZOLADEX treatment. If used during pregnancy, the patient should be apprised of the potential hazard to the fetus. ZOLADEX can cause fetal harm when administered to a pregnant woman. ZOLADEX is contraindicated during pregnancy unless used for palliative treatment of advanced breast cancer. ZOLADEX is contraindicated in patients with a known hypersensitivity to GnRH, GnRH agonist analogues, or any of the components in ZOLADEX. Eli Lilly and Company.Īnaphylactic reactions to ZOLADEX have been reported in the medical literature. Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. Overall survival with ribociclib plus endocrine therapy in breast cancer. Adjuvant endocrine therapy in breast cancer: evolving paradigms in premenopausal women. Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |